Concepts (142)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Benzo(a)pyrene | 11 | 2020 | 126 | 1.930 |
Why?
|
| Hydroxyurea | 3 | 2023 | 34 | 1.320 |
Why?
|
| Testis | 7 | 2023 | 187 | 1.240 |
Why?
|
| Hypogonadism | 2 | 2023 | 21 | 1.240 |
Why?
|
| Endocrine Disruptors | 5 | 2023 | 39 | 0.990 |
Why?
|
| Carcinogens | 3 | 2012 | 124 | 0.690 |
Why?
|
| Ovary | 4 | 2013 | 108 | 0.680 |
Why?
|
| Fertility | 3 | 2023 | 59 | 0.640 |
Why?
|
| Infertility, Male | 2 | 2014 | 45 | 0.450 |
Why?
|
| Fetus | 1 | 2012 | 105 | 0.420 |
Why?
|
| Rats, Inbred F344 | 8 | 2012 | 245 | 0.410 |
Why?
|
| Premenstrual Syndrome | 2 | 2023 | 13 | 0.360 |
Why?
|
| Sperm Motility | 3 | 2023 | 38 | 0.360 |
Why?
|
| Antisickling Agents | 1 | 2009 | 15 | 0.340 |
Why?
|
| Environmental Pollutants | 5 | 2014 | 179 | 0.330 |
Why?
|
| Luteinizing Hormone | 4 | 2012 | 63 | 0.320 |
Why?
|
| Animals | 19 | 2023 | 15081 | 0.320 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2023 | 234 | 0.310 |
Why?
|
| Spermatozoa | 2 | 2014 | 200 | 0.300 |
Why?
|
| Testosterone | 6 | 2023 | 193 | 0.300 |
Why?
|
| Polycystic Ovary Syndrome | 3 | 2011 | 27 | 0.290 |
Why?
|
| Anemia, Sickle Cell | 1 | 2009 | 183 | 0.280 |
Why?
|
| Liver | 5 | 2020 | 479 | 0.280 |
Why?
|
| Rats | 10 | 2012 | 3483 | 0.270 |
Why?
|
| Epididymis | 1 | 2003 | 28 | 0.230 |
Why?
|
| Female | 19 | 2023 | 20969 | 0.230 |
Why?
|
| Semen | 1 | 2023 | 51 | 0.220 |
Why?
|
| Fetal Death | 1 | 2002 | 18 | 0.220 |
Why?
|
| Administration, Inhalation | 3 | 2012 | 80 | 0.220 |
Why?
|
| Mice | 9 | 2023 | 5913 | 0.220 |
Why?
|
| Male | 13 | 2023 | 20025 | 0.220 |
Why?
|
| Depressive Disorder, Major | 1 | 2023 | 103 | 0.210 |
Why?
|
| Spermatogenesis | 1 | 2023 | 155 | 0.200 |
Why?
|
| Estrogens | 3 | 2023 | 202 | 0.190 |
Why?
|
| Atmospheric Pressure | 1 | 2020 | 11 | 0.180 |
Why?
|
| Pressure | 1 | 2020 | 43 | 0.180 |
Why?
|
| Metformin | 2 | 2011 | 65 | 0.180 |
Why?
|
| Chromatography, Liquid | 1 | 2020 | 142 | 0.170 |
Why?
|
| Contraceptives, Oral | 1 | 2018 | 14 | 0.160 |
Why?
|
| Progestins | 1 | 2018 | 12 | 0.160 |
Why?
|
| Mass Spectrometry | 1 | 2020 | 260 | 0.160 |
Why?
|
| Litter Size | 2 | 2012 | 15 | 0.160 |
Why?
|
| Endometriosis | 1 | 2020 | 73 | 0.160 |
Why?
|
| Progesterone | 2 | 2012 | 113 | 0.160 |
Why?
|
| Inhalation Exposure | 2 | 2008 | 43 | 0.160 |
Why?
|
| Colonic Neoplasms | 1 | 2020 | 186 | 0.150 |
Why?
|
| Contraception | 1 | 2018 | 57 | 0.150 |
Why?
|
| Depressive Disorder | 1 | 2018 | 174 | 0.140 |
Why?
|
| Disease Models, Animal | 4 | 2020 | 1371 | 0.140 |
Why?
|
| Microsomes, Liver | 2 | 2007 | 70 | 0.140 |
Why?
|
| Arrestins | 1 | 2015 | 27 | 0.130 |
Why?
|
| Ovulation | 2 | 2012 | 20 | 0.130 |
Why?
|
| Estrous Cycle | 2 | 2012 | 35 | 0.130 |
Why?
|
| Caloric Restriction | 2 | 2011 | 32 | 0.120 |
Why?
|
| Receptors, FSH | 2 | 2012 | 7 | 0.120 |
Why?
|
| Biological Availability | 4 | 2010 | 88 | 0.110 |
Why?
|
| Premature Birth | 1 | 2014 | 75 | 0.110 |
Why?
|
| Prolactin | 2 | 2023 | 62 | 0.110 |
Why?
|
| Microsomes | 3 | 2009 | 52 | 0.110 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2014 | 162 | 0.110 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2012 | 43 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2010 | 1039 | 0.110 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2012 | 52 | 0.100 |
Why?
|
| Bone Marrow Transplantation | 1 | 2012 | 15 | 0.100 |
Why?
|
| Ovarian Follicle | 1 | 2012 | 35 | 0.100 |
Why?
|
| Estradiol | 1 | 2012 | 262 | 0.090 |
Why?
|
| Risk Reduction Behavior | 1 | 2011 | 127 | 0.090 |
Why?
|
| DNA Adducts | 1 | 2010 | 42 | 0.090 |
Why?
|
| Blastocyst | 1 | 2010 | 48 | 0.090 |
Why?
|
| Inflammation | 1 | 2014 | 618 | 0.090 |
Why?
|
| Lung | 1 | 2012 | 446 | 0.090 |
Why?
|
| Mice, Inbred ICR | 1 | 2009 | 40 | 0.080 |
Why?
|
| Depression | 1 | 2015 | 712 | 0.080 |
Why?
|
| Hypoglycemic Agents | 1 | 2010 | 160 | 0.080 |
Why?
|
| Phenotype | 1 | 2011 | 689 | 0.080 |
Why?
|
| Radioimmunoassay | 2 | 2010 | 65 | 0.080 |
Why?
|
| Organ Size | 1 | 2008 | 157 | 0.080 |
Why?
|
| Random Allocation | 1 | 2008 | 139 | 0.080 |
Why?
|
| Pregnancy | 3 | 2014 | 1549 | 0.080 |
Why?
|
| Time Factors | 2 | 2011 | 1742 | 0.070 |
Why?
|
| Mice, Transgenic | 1 | 2009 | 617 | 0.070 |
Why?
|
| Humans | 11 | 2023 | 37093 | 0.070 |
Why?
|
| Intestine, Small | 1 | 2005 | 25 | 0.070 |
Why?
|
| Fluorenes | 1 | 2005 | 26 | 0.070 |
Why?
|
| Exercise | 1 | 2010 | 613 | 0.060 |
Why?
|
| Fluorescence | 2 | 2020 | 121 | 0.060 |
Why?
|
| Neurosecretory Systems | 1 | 2023 | 16 | 0.060 |
Why?
|
| Sheep | 3 | 2009 | 72 | 0.060 |
Why?
|
| Reproduction | 1 | 2023 | 71 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2005 | 433 | 0.060 |
Why?
|
| Treatment Outcome | 3 | 2012 | 1369 | 0.060 |
Why?
|
| Swine | 3 | 2009 | 184 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2018 | 661 | 0.050 |
Why?
|
| Maternal Exposure | 1 | 2002 | 33 | 0.050 |
Why?
|
| Embryo Implantation | 1 | 2002 | 32 | 0.050 |
Why?
|
| Embryonic Development | 1 | 2002 | 76 | 0.050 |
Why?
|
| Cattle | 3 | 2009 | 477 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 3 | 2014 | 1609 | 0.050 |
Why?
|
| Carcinogens, Environmental | 1 | 2001 | 35 | 0.050 |
Why?
|
| Young Adult | 3 | 2018 | 4268 | 0.050 |
Why?
|
| Adult | 5 | 2018 | 11712 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2011 | 286 | 0.050 |
Why?
|
| Porosity | 1 | 2020 | 32 | 0.050 |
Why?
|
| Adolescent | 3 | 2018 | 5363 | 0.050 |
Why?
|
| Solvents | 1 | 2020 | 99 | 0.040 |
Why?
|
| Stereoisomerism | 1 | 2020 | 167 | 0.040 |
Why?
|
| Tennessee | 1 | 2018 | 70 | 0.040 |
Why?
|
| Sexual Behavior | 1 | 2023 | 609 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2012 | 933 | 0.040 |
Why?
|
| Water | 1 | 2020 | 296 | 0.040 |
Why?
|
| Risk Factors | 2 | 2018 | 3562 | 0.040 |
Why?
|
| Quality of Life | 2 | 2011 | 481 | 0.040 |
Why?
|
| Cricetinae | 2 | 2007 | 238 | 0.030 |
Why?
|
| Species Specificity | 2 | 2007 | 245 | 0.030 |
Why?
|
| Administration, Oral | 2 | 2010 | 224 | 0.030 |
Why?
|
| Subcellular Fractions | 1 | 2013 | 77 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2005 | 421 | 0.020 |
Why?
|
| Placebo Effect | 1 | 2010 | 13 | 0.020 |
Why?
|
| Glycemic Index | 1 | 2010 | 8 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 148 | 0.020 |
Why?
|
| Diet, Reducing | 1 | 2010 | 24 | 0.020 |
Why?
|
| Exercise Therapy | 1 | 2011 | 69 | 0.020 |
Why?
|
| Patient Dropouts | 1 | 2010 | 29 | 0.020 |
Why?
|
| Ovulation Induction | 1 | 2010 | 6 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2011 | 455 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2010 | 62 | 0.020 |
Why?
|
| Plasma | 1 | 2010 | 31 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2010 | 158 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2010 | 97 | 0.020 |
Why?
|
| Gene Expression | 1 | 2012 | 674 | 0.020 |
Why?
|
| Life Style | 1 | 2010 | 308 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2011 | 753 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 623 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2011 | 1130 | 0.020 |
Why?
|
| Mesocricetus | 1 | 2007 | 54 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2007 | 129 | 0.020 |
Why?
|
| Goats | 1 | 2005 | 19 | 0.020 |
Why?
|
| Haplorhini | 1 | 2005 | 22 | 0.020 |
Why?
|
| Dogs | 1 | 2005 | 149 | 0.020 |
Why?
|
| Genitalia, Male | 1 | 2001 | 13 | 0.010 |
Why?
|
| United States | 1 | 2011 | 4223 | 0.010 |
Why?
|
| Middle Aged | 1 | 2005 | 10129 | 0.010 |
Why?
|